{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T21:42:25Z","timestamp":1783633345380,"version":"3.55.0"},"reference-count":15,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2002,6,1]],"date-time":"2002-06-01T00:00:00Z","timestamp":1022889600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2002,6,1]],"date-time":"2002-06-01T00:00:00Z","timestamp":1022889600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2002,6]]},"DOI":"10.3816\/cbc.2002.n.020","type":"journal-article","created":{"date-parts":[[2008,9,10]],"date-time":"2008-09-10T21:04:46Z","timestamp":1221080686000},"page":"153-159","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":64,"title":["The Study of Tamoxifen and Raloxifene: Preliminary Enrollment Data from a Randomized Breast Cancer Risk Reduction Trial"],"prefix":"10.3816","volume":"3","author":[{"given":"Victor G.","family":"Vogel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph P.","family":"Costantino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Lawrence","family":"Wickerham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter M.","family":"Cronin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norman","family":"Wolmark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.3816\/CBC.2002.n.020_bib1","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","article-title":"Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study","volume":"90","author":"Fisher","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"10.3816\/CBC.2002.n.020_bib2","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1093\/jnci\/91.21.1829","article-title":"Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer","volume":"91","author":"Gail","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"10.3816\/CBC.2002.n.020_bib3","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","article-title":"Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) investigators","volume":"282","author":"Ettinger","year":"1999","journal-title":"JAMA"},{"key":"10.3816\/CBC.2002.n.020_bib4","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1001\/jama.281.23.2189","article-title":"The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation","volume":"281","author":"Cummings","year":"1999","journal-title":"JAMA"},{"key":"10.3816\/CBC.2002.n.020_bib5","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1093\/jnci\/81.24.1879","article-title":"Projecting individualized probabilities of developing breast cancer for white females who are being examined annually","volume":"81","author":"Gail","year":"1989","journal-title":"J Natl Cancer Inst"},{"key":"10.3816\/CBC.2002.n.020_bib6","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/jnci\/91.18.1541","article-title":"Validation studies for models projecting the risk of invasive and total breast cancer incidence","volume":"91","author":"Costantino","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"10.3816\/CBC.2002.n.020_bib7","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0140-6736(98)04394-3","article-title":"Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study","volume":"352","author":"Veronesi","year":"1998","journal-title":"Lancet"},{"key":"10.3816\/CBC.2002.n.020_bib8","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJM198501173120303","article-title":"Risk factors for breast cancer in women with proliferative breast disease","volume":"312","author":"Dupont","year":"1985","journal-title":"N Engl J Med"},{"key":"10.3816\/CBC.2002.n.020_bib9","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1056\/NEJM199407073310103","article-title":"Long-term risk of breast cancer in women with fibroadenoma","volume":"331","author":"Dupont","year":"1994","journal-title":"N Engl J Med"},{"key":"10.3816\/CBC.2002.n.020_bib10","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/1097-0142(19950701)76:1<46::AID-CNCR2820760107>3.0.CO;2-B","article-title":"Factors related to enrollment in the breast cancer prevention trial at a comprehensive cancer center during the first year of recruitment","volume":"76","author":"Yeomans-Kinney","year":"1995","journal-title":"Cancer"},{"key":"10.3816\/CBC.2002.n.020_bib11","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1006\/pmed.1998.0349","article-title":"The effect of physician recommendation on enrollment in the Breast Cancer Chemoprevention Trial","volume":"27","author":"Kinney","year":"1998","journal-title":"Prev Med"},{"key":"10.3816\/CBC.2002.n.020_bib12","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1200\/JCO.1999.17.9.2659","article-title":"Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study","volume":"17","author":"Day","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2002.n.020_bib13","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1093\/jnci\/93.21.1615","article-title":"Tamoxifen and depression: more evidence from the National Surgical Adjuvant Breast and Bowel Project's Breast Cancer Prevention (P-1) Randomized Study","volume":"93","author":"Day","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"10.3816\/CBC.2002.n.020_bib14","series-title":"Management of Patients at High Risk for Breast Cancer","first-page":"201","article-title":"Chemoprevention: reducing breast cancer risk","author":"Vogel","year":"2001"},{"key":"10.3816\/CBC.2002.n.020_bib15","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/S0140-6736(02)09088-8","article-title":"Anastrozole alone or in combination with tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial","volume":"359","author":"The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group","year":"2002","journal-title":"Lancet"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820911701677?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820911701677?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:06:13Z","timestamp":1761512773000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820911701677"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,6]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2002,6]]}},"alternative-id":["S1526820911701677"],"URL":"https:\/\/doi.org\/10.3816\/cbc.2002.n.020","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2002,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Study of Tamoxifen and Raloxifene: Preliminary Enrollment Data from a Randomized Breast Cancer Risk Reduction Trial","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.3816\/CBC.2002.n.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2002 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}